Predicting cisplatin tolerability in older adults with head and neck cancer – Insights for improved chemoradiation outcomes

We developed predictive models to support clinicians in identifying older adults with HNSCC capable of tolerating ≥ 200 mg/m<sup>2</sup> cumulative cisplatin during chemoradiation. Once validated, these models could improve personalized treatments and enhance shared decision-making in older adults with HNSCC.

Authors

Institutions

Publication Details

Journal
Radiotherapy and Oncology
Published
2024-12-24
DOI
https://doi.org/10.1016/j.radonc.2024.110697
Citations
5
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
2.90
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predicting cisplatin tolerability in older adults with head and neck cancer – Insights for improved chemoradiation outcomes

Marcelo Raul Bonomi, Carmen Stromberger, M. Weymann, Sebastian Marschner et al.
5 citations
Radiotherapy and Oncology
Head and Neck Cancer Studies
2.90
article

Predicting cisplatin tolerability in older adults with head and neck cancer – Insights for improved chemoradiation outcomes

Marcelo Raul Bonomi, Carmen Stromberger, M. Weymann, Sebastian Marschner, Harald Binder, Carmen Kut, Daniel R. Dickstein, Clemens Seidel, Alev Altay-Langguth, Erik Haehl, Alexander Fabian, Johannes Kraft, Sachin R. Jhawar, Peter Hambsch, Harry Quon, Arnulf Mayer, Claus Belka, Max Behrens, Sören Schnellhardt, Anca-Ligia Grosu, Alexander Rühle, Heinz Schmidberger, Carolin Senger, Goda Kalinauskaitė, Sujith Baliga, Panagiotis Balermpas, Dukagjin M. Blakaj, Marlen Haderlein, Thomas Kuhnt, Esmée L. Looman, Victor Lewitzki, Jens von der Grün, Claudia Leucht, Constantinos Zamboglou, Jörg Andreas Müller, Justus Domschikowski, Nils H. Nicolay, Eric Yu Hai Chen, Konstantinos Ferentinos, A.N. Elguindy, Benjamin P. Bakst, Johannes Olbrich
article en
5 citations

Abstract

We developed predictive models to support clinicians in identifying older adults with HNSCC capable of tolerating ≥ 200 mg/m<sup>2</sup> cumulative cisplatin during chemoradiation. Once validated, these models could improve personalized treatments and enhance shared decision-making in older adults with HNSCC.

Radiotherapy and OncologyVol. 204
Goethe University Frankfurt (DE), Johns Hopkins University (US), University of Freiburg (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), European University Cyprus (CY), University of Zurich (CH), Heidelberg University (DE), University Medical Center Freiburg (DE), University Hospital Heidelberg (DE), The Ohio State University Wexner Medical Center (US), University of Cyprus (CY), Humboldt-Universität zu Berlin (DE), Universitätsklinikum Erlangen (DE), University Hospital of Zurich (CH), German Cancer Society (DE), University Hospital Schleswig-Holstein (DE), University Hospitals Seidman Cancer Center (US), University Hospital Leipzig (DE), Universitätsklinikum Würzburg (DE), Comprehensive Cancer Center Erlangen (DE), University Hospital in Halle (DE), Ludwig-Maximilians-Universität München (DE), College of Mount Saint Vincent (US), Leipzig University (DE), University of Lübeck (DE), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 8%
Head and Neck Cancer Studies
2.90
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.